August 29, 2026 · Vialen Health

For years, CAR-T progress in solid tumors remained largely within early clinical research. In June 2026, China’s NMPA approved satri-cel for CLDN18.2-positive, HER2-negative advanced gastric or gastro-esophageal junction cancer. The significance is specific: a biomarker-defined CAR-T moved into commercial treatment in one market.

WHAT CHANGED
The approval created a commercial treatment context for a selected solid-tumor population. It did not establish CAR-T as a general treatment for solid tumors, nor did it make the therapy available in every healthcare system.

WHY CLDN18.2 MATTERS
CLDN18.2 expression is a treatment-defining biomarker. The testing method, specimen, expression result, and the treating program’s criteria matter. A diagnosis of gastric cancer alone is not enough.

WHY HER2 AND PRIOR THERAPY MATTER
HER2 status, prior systemic treatment, treatment response or progression, current disease burden, organ function, and clinical status help define whether review is relevant.

FROM RESEARCH TO COMMERCIAL TREATMENT
The evidence base includes phase 1 and phase 2 investigation. Commercial authorization changes the access context in China, but review remains case-specific and centre-controlled.

INTERNATIONAL RELEVANCE
For a patient outside China, treatment existence is only the first question. A credible route also requires a verified intake process, pathology and biomarker review, records transfer, preliminary episode structure, economics and timing when available, and clear clinical responsibility.

VIALEN’S REVIEW STANDARD
Market authorization does not automatically mean a therapy is appropriate or practically available for a particular case. Vialen proceeds only when intake and clinical-review requirements can be met and verified. The treating institution determines eligibility and treatment.

References
Qi C et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers. Nature Medicine (2022) — https://www.nature.com/articles/s41591-022-01800-8
ClinicalTrials.gov NCT03874897 — https://clinicaltrials.gov/study/NCT03874897
CARsgen Therapeutics, June 22, 2026 — https://www.carsgen.com/en/news/20260622/